Lexaria Bioscience (LEXX) Stock Statistics & Valuation Metrics

Lexaria Bioscience has a market cap or net worth of $15.89M. The enterprise value is $7.27M.

Lexaria Bioscience has 24,787,445 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lexaria Bioscience’s return on equity (ROE) is -3.98 and return on invested capital (ROIC) is -438.07%.

The current PE Ratio of Lexaria Bioscience is ―. Lexaria Bioscience’s PEG ratio is -0.03.

In the last 12 months, Lexaria Bioscience had revenue of 705.92K and earned -11.90M in profits. Earnings per share was -0.66.

In the last 12 months, operating cash flow was -9.37M and capital expenditures -55.91K, giving a free cash flow of -9.43M billion.

Lexaria Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Lexaria Bioscience upcoming earnings date is Apr 14, 2023, After Close (Confirmed).

Lexaria Bioscience as a current ratio of 2.32, with Debt / Equity ratio of 1.43%

In the past 12 months, Lexaria Bioscience has paid 0.00 in taxes.

Lexaria Bioscience EV to EBITDA ratio is -1.20, with an EV/FCF ratio of -1.35.

Lexaria Bioscience has $5.27M in cash and marketable securities with $94.39K in debt, giving a net cash position of $5.18M billion.

Gross margin is 100.00%, with operating margin of -1683.01%, and net profit margin of -1686.00%.

The average price target for Lexaria Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―